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We report an unexpected role for protease signaling
in neural tube closure and the formation of the central
nervous system. Mouse embryos lacking protease-
activated receptors 1 and 2 showed defective hind-
brain and posterior neuropore closure and devel-
oped exencephaly and spina bifida, important
human congenital anomalies. Par1 and Par2 were
expressed in surface ectoderm, and Par2 was ex-
pressed selectively along the line of closure. Ablation
of Gi/z and Rac1 function in these Par2-expressing
cells disrupted neural tube closure, further impli-
cating G protein-coupled receptors and identifying
a likely effector pathway. Cluster analysis of protease
and Par2 expression patterns revealed a group of
membrane-tethered proteases often coexpressed
with Par2. Among these, matriptase activated Par2
with picomolar potency, and hepsin and prostasin
activated matriptase. Together, our results suggest
a role for protease-activated receptor signaling in
neural tube closure and identify a local protease
network that may trigger Par2 signaling and monitor
and regulate epithelial integrity in this context.
INTRODUCTION
Protease-activated receptors (PARs) are G protein-coupled
receptors (GPCRs) that allow cells to sense specific proteases
in their environment (Coughlin, 2000; Vu et al., 1991). Four
PARs are found in humans and mice. PARs 1, 3, and 4 mediate
cellular responses to the coagulation protease thrombin. PAR2 is
not activated effectively by thrombin but can be activated by
a variety of serine proteases with trypsin-like specificity,
including the coagulation proteases tissue factor/factor VIIa
and factor Xa (Camerer et al., 2000; Riewald and Ruf, 2001).DeveStudies in cell culture, animal models, and humans support
the view that, in the adult, PARs and the coagulation cascade
couple tissue injury with vascular damage to appropriate cellular
responses that regulate hemostasis, inflammation, cell survival,
and tissue repair (Becker et al., 2009; Camerer et al., 2004;
Coughlin, 2000; Coughlin and Camerer, 2003; Guo et al., 2004;
Kahn et al., 1999; Sambrano et al., 2001; Vergnolle et al., 2001).
Less is known regarding the roles of PARs and the proteases
that activate them in contexts other than tissue injury, particularly
in embryonic development. Par1-deficient mouse embryos
exhibit partially penetrant lethality at midgestation due to lack
of Par1 signaling in endothelial cells (Connolly et al., 1996; Griffin
et al., 2001). This phenotype is less penetrant and less severe
than that associated with knockout of tissue factor, the trigger
for coagulation (Mackman, 2004). Toward testing the possibility
that this difference might be due to partially redundant functions
of Par1 and other PARs downstream of tissue factor and the
coagulation cascade, we generated mice lacking multiple PARs
and uncovered an unexpected phenotype associated with
combined knockout of the genes encoding Par1 and Par2: failed
neural tube closure. We also characterized a set of membrane-
tethered proteases that may comprise a local protease network
that activates Par2 during neural tube closure, and we identified
Gi and Rac as candidate downstream effectors of Par2 and other
GPCRs in this process. This system appears to operate in the
surface ectoderm along the line of closure. Together, our studies
identify an unexpected role for local protease/PAR signaling in
neural tube closure, a process that is critical for the formation
of the central nervous system and that goes awry in the congen-
ital anomalies exencephaly and spina bifida.
RESULTS
Combined Deficiency in Par1 and Par2 Results
in Defective Neural Tube Closure
Par1andPar2 are just 76 kbapart onmousechromosome13 (see
Experimental Procedures for gene nomenclature). Given this
linkage, we generated the Par1:Par2 double knockout by usinglopmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Inc. 25
Figure 1. Phenotypes Associated with
Combined Deficiency of Par2 and Par1
(A) ThreephenotypesexhibitedbyPar1/:Par2/
embryos: midgestational cardiovascular failure
(top left), late-gestational death associated with
edema (top center), and exencephaly (top right).
Par1/:Par2/ embryos that survived to birth
showed anencephaly and spina bifida with incom-
plete penetrance (lower left; from left to right: curly
tail, spina bifida/curly tail, anencephaly, anen-
cephaly and spina bifida/curly tail). A surviving
adult with curly tail is at the lower right.
(B and C) Viability and presence of exencephaly at
(B) various gestational ages and in the presence or
absence of an (C) endothelial Par1 transgene;
number alive (number with exencephaly) is shown.
Embryos in (C) were collected at 12.5–14.5 dpc.
(DandE)Embryos fromPar1+/:Par2+/3Par1/:
Par2/ crosses were collected at 9.5 dpc, scored
for an open (HO) or closed (HC) hindbrain neuro-
pore and somite count, then genotyped. To visu-
alize the neuropore, embryos were X-gal stained.
(E) Results from embryos in (D) with 15 or more
somites. See also Figure S1.
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embryonic stem (ES) cells in which thePar2 gene had been previ-
ously targeted (Camerer et al., 2002). Each recombination
inserted a b-galactosidase (lacZ) coding sequence at the start
codon so as to substitute lacZ for Par1 and Par2 expression
(Griffin et al., 2001) (Figure S1A, available online). Crosses of
Par1+/:Par2+/ mice generated from ES cells in which Par1
and Par2 were disrupted on the same chromosome produced
live Par1/:Par2/ offspring at weaning at 4.6%–7.6% of the
expected Mendelian rate in a mixed 129/BL6 background (Fig-
ure S1B). In the same genetic background, Par1+/ crosses
produced Par1/ offspring at 50% of the expected rate, and
Par2+/ crosses produced Par2/ offspring at 85% of the
expected rate (Connolly et al., 1996; Damiano et al., 1999; Griffin
et al., 2001; data not shown). Thus, the combined deficiency of
Par1 and Par2 produced much more penetrant embryonic
lethality than isolated Par1 or Par2 deficiency. Par1/:Par2/
embryos showed three different phenotypes, each partially
penetrant: midgestational cardiovascular failure beginning at
9.5 days postcoitus (dpc), as previously described with isolated
Par1deficiency (Connolly et al., 1996;Griffin et al., 2001); exence-
phaly; and late gestational lethality associated with widespread
edema (Figure 1A). In the same strain background, exencephaly
was not observed in either single knockout, and late gestational
lethality was seen only infrequently in Par2/ embryos. Thus,
these two phenotypes appear to reflect interacting roles of Par1
and Par2 in the developing embryo. Occasionally, Par1/:
Par2/ mice did survive embryonic development, and these
mice sometimes exhibited spina bifida and curly tail (Figure 1A).
Exencephaly, spina bifida, and curly tail are all hallmarks of failed
neural tube closure (Copp et al., 2003). Thus, Par1/:Par2/
mice appeared to have an incompletely penetrant defect in26 Developmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Inclosure of both the hindbrain and posterior neuropores. Because
no role for PARs in the development of the nervous system has
been described, we focused on characterizing this phenotype.
Exencephaly was detectable by gross inspection beginning at
11.5 dpc; 17/51 (33%) viablePar1/:Par2/ embryos exhibited
exencephaly after that time (Figures 1A and 1B). Restoring Par1
expression in endothelial cells with a Tie2p/e-Par1 transgene
(Griffin et al., 2001) rescued the midgestational lethality in
Par1/:Par2/ embryos but did not prevent exencephaly
(Figure 1C), implying that neither loss of Par1 function in endo-
thelial cells nor midgestational cardiovascular failure contributed
to the exencephaly phenotype.
Exencephaly is due to defective closure of the hindbrain
neuropore. To directly assess neuropore closure, we scored
embryos from Par1/:Par2/ 3 Par1+/:Par2+/ crosses for
an open or closed hindbrain neuropore and somite count before
genotyping. A total of 22% of Par1+/:Par2+/ embryos collected
at 9.5 dpc had open hindbrain neuropores, compared to 47% of
Par1/:Par2/ embryos (Figure 1D). Among embryos that had
progressed to the 15-somite stage or beyond, only 4% of con-
trols had open neuropores versus 32% of mutants (Figures 1D
and 1E). The latter frequency is similar to the overall penetrance
of exencephaly in the mutants. These results suggest that exen-
cephaly in Par1/:Par2/ embryos is a result of the failed
closure of the hindbrain neuropore, and that such failure is not
simply a result of developmental delay.
Par2 Is Expressed in the Surface Ectoderm Adjacent
to the Neuroepithelium at the Time and Place of Neural
Tube Closure
A direct role for PARs in neural tube closure would demand
expression of the receptors in or around the neural tube at thec.
Figure 2. Localized Expression of Par2 in Surface Ectoderm and Characterization of a Surface Ectoderm Cre (Grhl3Cre)
(A–C) Par2 expression at the time of neural tube closure. (A andB) X-gal staining of a Par2-lacZ knockin embryo in (A) wholemount and (B) cross-section. (C) In situ
hybridization of wild-type embryos for Par2 mRNA.
(D and E) LacZ expression from a Cre-IRES-NLSlacZ cassette inserted into the Grhl3 locus (Grhl3Cre; see Figure S3).
(F) In situ hybridization of a wild-type embryo for Grhl3 mRNA. Sense controls for (C) and (F) are in Figure S2. Embryos were collected at 9.25 dpc.
Developmental Cell
Protease Signaling Promotes Neural Tube Closuretime of closure. b-galactosidase staining of Par2-LacZ knockin
embryos revealed expression of Par2 in the surface ectoderm
cells immediately overlying the neuroepithelium at the time and
place of fusion (Figures 2A and 2B; Figures S2A and S2B). Such
localized Par2 expression was confirmed by in situ hybridization
of wild-type embryos for Par2mRNA (Figure 2C; Figure S2C). By
the same measures, Par1 expression was detected in endocar-
dium, endothelium, and a subset of hematopoietic cells, but not
in surface ectoderm (Figure S2D). However, Par1 mRNA was
readily detected by quantitative PCR of RNA from fluores-
cence-activated cell sorting (FACS)-sorted surface ectoderm
cells (see below), suggesting that Par1 is probably expressed in
surface ectoderm at levels below the detection limits of the other
techniques. Thus, although we cannot exclude less direct mech-
anisms, the requirement for knockout of both Par1 and Par2 for
theappearanceof exencephalymaybedue topartially redundant
functions of these receptors in the surface ectoderm.
Together with the exencephaly phenotype in Par1/:Par2/
embryos, the precise expression of Par2 at the time and place of
neural tube closure suggested an unexpected role for local Par2
signaling in surface ectoderm in neural tube closure. These
observations prompted an effort to obtain independent evidence
for the importance of GPCR signaling in surface ectoderm during
neural tube closure.
Surface Ectoderm-Specific Knockout of Gi and Rac1
Function, Signaling Pathways Downstream of Par2,
Causes Neural Tube Defects
If loss of GPCR function in surface ectoderm is responsible for
the neural tube closure defects described above, surface ecto-
derm-specific knockout of the relevant signaling pathway(s)Devedownstream of GPCRs should also cause neural tube defects.
To manipulate genes in surface ectoderm, we generated mice
in which a Cre-IRES-NLSlacZ cassette was inserted in the Grai-
nyhead-like-3 (Grhl3) gene (Figure S3A), hereafter designated
Grhl3Cre/+ mice. Grhl3 is a transcription factor expressed in
surface ectoderm, hindgut endoderm, and other epithelial cells
in a pattern similar to Par2 at the time of neural tube closure
(Figure 2 and Figure S2), and loss of Grhl3 function causes exen-
cephaly and spina bifida in knockout and curly tail (ct/ct) mutant
mice (Auden et al., 2006; Gustavsson et al., 2007; Ting et al.,
2003). X-gal staining of Grhl3Cre/+ embryos collected at 8.5 dpc
confirmed NLSlacZ expression in surface ectoderm along the
neural ridge in a pattern that was indistinguishable from Par2
(Figure 2); expression quickly spread laterally from the neural
ridge to cover much of the surface ectoderm. In accord, exami-
nation of Grhl3Cre/+ embryos carrying a cytoplasmic lacZ or YFP
Cre excision reporter revealed reporter expression, first in the
midline, then spreading laterally in the surface ectoderm to cover
the embryo (Figures S3B–S3D). Thus, the Grhl3Cre allele drove
efficient and relatively tissue-specific excision of floxed
sequences in surface ectoderm. Grhl3Cre/Cre embryos (effec-
tively Grhl3 nulls) recapitulated the neural tube defect pheno-
types reported for Grhl3/ embryos (Ting et al., 2003), but,
importantly,Grhl3Cre/+ embryos (effectivelyGrhl3 heterozygotes)
had no neural tube phenotype in the absence of a relevant floxed
target allele.
Par1 and Par2 can couple to members of the Gq/11, Gi/o/z, and
G12/13 G protein subfamilies (Coughlin, 2000), although Par2
coupling to G12/13 may be less effective than Par1 (Vouret-Cra-
viari et al., 2003). Combined deficiency in Gaq and Ga11 causes
embryonic lethality around 11 dpc; neural tube defects werelopmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Inc. 27
Figure 3. Abrogating Gi Function and Rac1 Expression in Surface Ectoderm Causes Neural Tube Defects
(A) Exencephaly inPar1/:Par2/,Grhl3Cre/+:ROSA26PTX/+:Gaz
/, andGrhl3Cre/+:Rac1f/f embryos collected at 14.5 dpc. Spina bifida and curly tail inGrhl3Cre/+:
ROSA26PTX/+: Gaz
/ (lower) and Grhl3Cre/+:Rac1f/f (both) embryos.
(B) Occurrence of neural tube defects (# with NTD/# live [%]) by genotype at 14.5 dpc. See also Figure S3.
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Gna13) is an important GPCR effector in endothelial cells and
neural crest during embryonic development, and Ga13 signaling
in neural crest contributes to neural tube closure (Ruppel et al.,
2005). To determine whether Ga13 in surface ectoderm might
also contribute to neural tube closure, we generated surface
ectoderm-specific Ga13 knockouts. Grhl3
Cre/+:Ga13
f/f embryos
lived through 14.5 dpc and did not display exencephaly.
Addressing possible redundancy with Ga12, we found that
Grhl3Cre/+:Ga13
f/f:Ga12
/ embryos died by 10.5 dpc with turning
and other defects, but with a closed hindbrain neuropore (data
not shown). Thus, loss of Ga12/13 signaling in surface ectoderm28 Developmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Inis unlikely to account for exencephaly in Par1/:Par2/
embryos.
We next addressed the role of the Gi/o/z family. Four of the five
widely expressed Gai/o/z family members (Gai1, Gai2, Gai3, and
Gao) are inhibited by pertussis toxin; Gaz is pertussis insensitive.
To circumvent redundancy among the Gai/o/z family members,
we used a ROSA26PTX conditional allele (Regard et al., 2007)
to express pertussis toxin S1 catalytic subunit (PTX) in surface
ectoderm by Cre-mediated excision of a Lox-Stop-Lox cassette.
Embryos from ROSA26PTX/PTX 3 Grhl3Cre/+ crosses were col-
lected at 14.5 dpc. Grhl3Cre/+:ROSA26PTX/+ embryos showed
exencephaly with a penetrance of 10% (Figure 3). Thec.
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ground. Exencephaly was not observed inmice lacking only Gaz,
nor in Cre-negative ROSA26PTX/+:Gaz
/ embryos. Posterior
neural tube defects—spina bifida and curly tail—were seen in
0%, 18%, and 40% of Grhl3Cre/+:ROSA26PTX/+ embryos in
Gaz
+/+, +/, and / backgrounds, respectively. Thus, PTX S1
expression in surface ectoderm and Gaz deficiency interacted
to promote neural tube defects, strongly supporting the notion
that these phenotypes are caused by loss of Gi/o/z pathway func-
tion, and hence that Gi signaling in surface ectoderm is required
for normal closure of the neural tube. In contrast to Grhl3Cre/+:
ROSA26PTX/+:Gaz
/ embryos, posterior neural tube defects
were rare in Par1/:Par2/ embryos. Grhl3 expression in
hindgut contributes to posterior neuropore closure (Gustavsson
et al., 2007). Although neural tube defects were not detected
in Grhl3Cre/+ embryos, it is possible that haploinsufficiency
of Grhl3 interacts with loss of Gi signaling in hindgut in
Grhl3Cre/+:ROSA26PTX/+:Gaz
/ embryos to produce such
defects. It is also possible that knockout of Gi pathway signaling
uncovered a role for Gi-coupled GPCRs in addition to Par2 and
Par1 in posterior neural tube closure.
Rac is one of several downstream effectors of Gi signaling.
Abrogation of Rac function impairs dorsal closure of the
Drosophila embryo cuticle due to an inability of opposing epithe-
lial sheets to migrate and fuse (Harden et al., 1995). Rac1 is the
main Rac family member expressed in nonhematopoietic tissues
in mice (Sugihara et al., 1998). To determine whether Rac func-
tion in surface ectoderm might be necessary for neural tube
closure in mouse embryos, we examined Grhl3Cre/+:Rac1f/f
embryos collected at 14.5 dpc (Figure 3). A total of 58% of
Grhl3Cre/+:Rac1f/f embryos displayed exencephaly versus 0%
for Cre-negative Rac1f/f embryos or Cre-positive embryos with
a single wild-type Rac1 allele (Figure 3). As with elimination of
Gi/o/z function in surface ectoderm, we also observed posterior
neural tube defects at a high rate (83%). Grhl3Cre/+:Rac1f/f
embryos were present at the expected Mendelian frequency,
and X-gal staining (for b-galactosidase expressed from the
IRES-lacZ included with the Grhl3 Cre knockin) demonstrated
that most surface ectoderm cells expressed Cre at this time.
Thus, Rac1 function was not required for the survival of surface
ectoderm cells. These results are consistent with a model in
which Gi-Rac signaling downstream of PARs and other GPCRs
in surface ectoderm contributes to neural tube closure.
Neural tube defects are often classified as sensitive or resis-
tant to folate supplementation (Copp et al., 2003). Folate injec-
tions of pregnant female mice (Fleming and Copp, 1998) at
7.5 and 8.5 dpc did not affect the penetrance of hindbrain or
posterior neural tube defects in Grhl3Cre/+:Rac1f/f embryos
collected at 14.5 dpc (Figure 3), suggesting that these defects
are folate resistant.
Identification of Candidate Par2-Activating Proteases
in the Context of Neural Tube Closure
Multiple serine proteases can activate Par2 in vitro, but its phys-
iological activators are uncertain. Uncovering a necessary role
for surface ectoderm Par2 in neural tube closure provided
a context in which to search for a Par2-activating protease.
Toward identifying candidate proteases, we first asked which
extracellular proteases are expressed in the mouse embryo atDevethe time of neural tube closure and which proteases are ex-
pressed in tissues in a pattern most like Par2.
We generated TaqMan-type qPCR primer/probe sets for the
125 genes in mouse predicted to encode a serine protease
that would reside in the extracellular compartment (e.g., prote-
ases with signal peptides, or type-2 transmembrane proteins
with extracellular protease domain [TTSPs]; Document S2 in
Supplemental Information [including a Microsoft Excel spread-
sheet of Taqman primer/probe sets used to identify candidate
protease agonists active during neural tube closure]) and used
these to quantitate mRNAs in mouse embryos collected at
8.5–9.5 dpc. Approximately 25% of the 125 protease genes
examined were expressed above background. We focused first
on the ten most abundantly expressed (Figure 4A), especially
in light of our cluster results (see below). Analysis of RNA
from FACS-sorted surface ectoderm cells from Grhl3Cre/+:
–ROSA26YFP/+ embryos collected at 8.5–9.5 dpc confirmed the
expression of nine of these ten in surface ectoderm, and
mRNA for four proteases—prostasin, epitheliasin, matriptase
(also known as MT-SP1 and St14), and hepsin—was enriched
in surface ectoderm relative to the rest of the embryo (Figure 4A).
Cluster analysis of the pattern of expression of the 125 prote-
ases and 11 selected inhibitors across 44 different tissues
in adult mice revealed matriptase (St14) and prostasin (Prss8),
their Kunitz-type inhibitors Hai-1 and Hai-2 (Spint1 and 2), and
epitheliasin (Tmprss2) to be expressed in a pattern most similar
to Par2 (F2rl1) (Figure 4B and Figure S7 [including an image that
displays the full hierarchical cluster analysis of protease, inhib-
itor, and receptor expression across mouse tissues]). Hepsin
was broadly expressed and did not specifically cluster with
Par2, but hepsin and Par2 were often expressed in the same
tissues. Prostasin, matriptase, hepsin, and epitheliasin are
membrane-tethered proteases and hence are likely to function
on or near the cell in which they are expressed. These results
raised the possibility that matriptase, prostasin, hepsin, and/or
epitheliasin might, together with Par2, comprise a local protease
signaling system in surface ectoderm. Our previous observation
that matriptase can activate Par2 heterologously expressed in
Xenopus oocytes (Takeuchi et al., 2000) encouraged investiga-
tion of this hypothesis.
In situ hybridization confirmed expression of prostasin, epithe-
liasin, matriptase, and hepsinmRNA in surface ectoderm of wild-
type embryos collected at 8.75 dpc; t-PA and Klk8 hybridization
was also detected and was more widespread (Figure 4C).
AlthoughMasp1was expressed in surface ectoderm (Figure 4A),
past studies had suggested that Masp1 was not an effective
Par2 activator (data not shown). Based on these results, we
chose Klk8, prostasin, tPA, epitheliasin, matriptase, and hepsin
for further study.
Par2 Cleavage and Signaling in Response to Candidate
Proteases
To determine whether these proteases might elicit signaling in
cells that express Par2 at natural levels, we examined phosphoi-
nositide (PI) hydrolysis in response to exogenous soluble
recombinant proteases added to cultures of HaCaT cells, a ker-
atinocyte-like surface ectoderm lineage cell line that naturally
expresses PAR1 and PAR2. At 50 nM, prostasin, matriptase,
and hepsin protease domains triggered PI hydrolysis in HaCaTlopmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Inc. 29
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Matriptase was remarkably potent in the HaCaT system, with
an EC50 of 200 pM; EC50 values for prostasin and hepsin
were 20 nM (Figure 5B). Responses were blocked by
recombinant ecotin or HAI-1 (data not shown), both broad-spec-
trum inhibitors of trypsin-fold serine proteases (Takeuchi et al.,
1999), confirming that responses to the recombinant protease
preparations were indeed due to protease activity.
To assess the ability of proteases to productively cleave indi-
vidual PARs, we transiently transfected HaCaT cells with Par1
and Par2 that had alkaline phosphatase (AP) fused to their
N-terminal exodomains such that receptor cleavage released AP
into the culturemedium (Ludeman et al., 2004). Addition of 10 nM
soluble recombinant matriptase to HaCaT cultures expressing
AP-Par2 released90%–95%of surface-available (trypsin-releas-
able) APwithin 60min in three indendent experiments, 20%–60%
was released by 10-20 nM prostasin, and hepsin showed some,
but variable, activity in this assay (Figure 5C; Figures S5 and S6).
None of these proteases released AP activity from cells express-
ing AP-Par2csm, an AP-Par2 mutant with a two amino acid
change that disrupts its activating cleavage site (Figure S5).
Thus, exposure to matriptase, prostasin, and hepsin resulted in
productive cleavage of Par2 expressed in HaCaT cells.
Unlike AP-Par2, AP release from AP-Par1-transfected HaCaT
cells by recombinant matriptase, prostasin, and hepsin was not
ablated by mutation of the activating cleavage site in Par1 (data
not shown). Par1 is subject to nonproductive cleavage and shed-
ding of its N-terminal exodomain by an ADAM17-like metallopro-
teinase (Ludeman et al., 2004), and prostasin, hepsin, and
matriptase failed to cause AP release from AP-Par1-transfected
HaCaT cells in the presence of the metalloproteinase inhibitor
1,10-phenanthroline (Figure S5). AP release fromAP-Par2-trans-
fected cells upon addition of prostasin, hepsin, and matriptase
was unaffected by metalloproteinase inhibition (Figure S5). Met-
alloproteinase-dependent Par1 shedding can be increased by
stimulation of protein kinase C (Ludeman et al., 2004). Thus,
PAR2 activation of metalloproteinase-dependent Par1 shedding
may account for release of AP fromAP-Par1 bymatriptase, pros-
tasin, and hepsin in the HaCaT system in the absence of metal-
loproteinase inhibition.
Evidence for a Par2-Activating Protease ‘‘Cascade’’
The experiments described above do not speak to whether
matriptase, prostasin, and/or hepsin act upon Par2 directly.
Toward addressing this question, we first examined the ability
of these proteases to trigger Par2 transfection-dependent PIFigure 4. Identification of Candidate Par2 Activators Expressed during
(A) Expression of 125 serine proteases predicted to reside in the extracellular s
8.5–9.5 dpc. The ten most abundantly expressed proteases relative to housekeep
in surface ectoderm (expression in YFP-positive surface ectoderm cells sorte
embryos relative to YFP-negative cells from the same embryos [2DDCT]) are show
(B) Hierarchical cluster analysis was used to compare the expression patterns of
time PCR of cDNA from 44 tissues and circulating cells from adult mice. The cluste
(Spint1) and Hai-2 (Spint2) is shown in TreeView; red intensity indicates increased
mation for experimental procedures.
(C) Surface ectoderm expression of mRNA for the indicated candidate proteas
controls are in insets.
(D) Immunostaining of live 8.5 dpc embryos with E2, an antibody specific for the ac
the hindbrain neuropore. A larger image is shown in Figure S4.
Devehydrolysis in lung fibroblasts from Par1-deficient mice (KOLF).
In the absence of transfection, KOLF do not express Par2 or
other PARs, matriptase, prostasin, hepsin, or Hai-1 mRNA as
assessed by TaqMan RT-PCR. In accord, even at 50 nM, exog-
enous matriptase, prostasin, and hepsin did not stimulate PI
hydrolysis in untransfected KOLFs (Figure 5D). After PAR2 trans-
fection of KOLFs, matriptase triggered signaling as effectively as
saturating concentrations of PAR2 agonist peptide and with an
EC50 of300 pM (Figures 5D and 5E), similar to that found in Ha-
CaT cultures (Figure 5B). Matriptase showed no activity in PAR1-
or PAR4-transfected KOLFs even at >1003 the EC50 for PAR2
(Figure 5D and data not shown). Similar results were obtained
regardless of whether mouse or human PAR cDNAs were trans-
fected. Activity at PAR3 was not examined because the mouse
homolog of this receptor is incapable of mediating transmem-
brane signaling (Nakanishi-Matsui et al., 2000).
Surprisingly, in contrast to the case in HaCaT cells, prostasin
produced no PI hydrolysis response in KOLFs transfected to
express PAR2 or other PARs (Figure 5D and data not shown).
Similarly, only a weak response to hepsin was detected (Figures
5D and 5E). The different protease responsiveness of HaCaT and
KOLF cultures suggested that KOLFs might lack a factor that
permits, or express an inhibitor that prevents, direct or indirect
PAR2 activation by prostasin and hepsin. Quantitative PCR anal-
ysis showed that matriptase was expressed by HaCaTs, but not
by KOLFs. This and the potency of matriptase as a PAR2 acti-
vator suggested that activation of the zymogen form of matrip-
tase by prostasin or hepsin might account for the ability of these
proteases to activate PAR2 in HaCaT cultures. To test this possi-
bility, we first determined whether matriptase inhibition would
attenuate signaling in response to prostasin and hepsin in HaCaT
cultures.
E2, a potent and highly selective antibody inhibitor to matrip-
tase (Farady et al., 2008; Sun et al., 2003), blocked the ability
of prostasin and hepsin to trigger PI hydrolysis in HaCaT cultures
(Figure 6A). E2 at the same concentration had no effect on
signaling by factor Xa (Figure 6A), which can directly activate
PAR2, nor did E2 inhibit the activity of 10 nM prostasin or hepsin
in amidolytic assays (data not shown). These results suggested
that prostasin and hepsin activated Par2 in HaCaTs by an indi-
rect mechanism that was matriptase dependent. To further
probe this possibility, we examined Par2 cleavage in KOLFs
with and without coexpression of matriptase. Hai-1 was coex-
pressed with matriptase in these experiments because matrip-
tase expression in the absence of its inhibitor appeared to be
toxic (data not shown). In contrast to soluble recombinantNeural Tube Closure
pace by real-time PCR of cDNA from pooled wild-type embryos collected at
ing genes (DCT), their abundance relative to Par2 (2DDCT), and their enrichment
d from dissociated Grhl3Cre+/:ROSA26YFP/+ [ROSA26 Lox-STOP-Lox YFP]
n.
125 candidate proteases, 11 select inhibitors, and Par2, as measured by real-
r containing Par2, matriptase (St14), prostasin (prss8), and their inhibitors Hai-1
expression. See Figure S7 for entire cluster analysis and Supplemental Infor-
es and Par2 by whole-mount in situ hybridization of 8.5 dpc embryos; sense
tive form of matriptase. Arrows indicate staining of surface ectoderm overlying
lopmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Inc. 31
Figure 5. Par2 Cleavage and Activation by Membrane-Associated Proteases
(A–E) (A, B, and E) Protease-triggered phosphoinositide (PI) hydrolysis in response to candidate Par2-activating proteases. (A) PI hydrolysis in HaCaT cultures
after the addition of soluble recombinant protease domains (50 nM) expressed as a percentage of the response to maximal concentrations of PAR-activating
peptides (100 mM TFLLRN + 100 mMSLIGRL). (B) Concentration response to protease domains that showed activity in (A). (C) Alkaline phosphatase (AP) release
upon addition of soluble protease domains to HaCaTs transiently expressing an N-terminal AP-Par2 fusion protein. See Figure S5 for cleavage site specificity and
PAR selectivity. (D) PI hydrolysis triggered by recombinant soluble protease domains or a maximal concentration (100 mM) of PAR1 or PAR2 peptide agonist (or
both peptides for untransfected KOLFs) in KOLFs stably transfected with PAR1 or PAR2. Similar results were obtained in three separate experiments. (E) PI
hydrolysis in PAR2-expressing KOLFs; concentration response to matriptase and hepsin. Data shown are mean ± SD.
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expressing AP-Par2 or AP-Par2 plus Hai-1 did not trigger AP
release. However, soluble recombinant prostasin did release
AP from KOLFs expressing AP-Par2 and Hai-1 plus matriptase,
but not active sitemutant matriptase nor amatriptasemutated at
the site required for proteolytic processing of the matriptase
zymogen to the active form (Figure 6B; Figure S6). Thus, Par2
cleavage by prostasin required expression of matriptase with
an intact active site and an intact zymogen conversion site,
consistent with a model in which prostasin activates Par2 by
activating matriptase zymogen coexpressed in the same or32 Developmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Innearby cells. Similar results were obtained with hepsin, but hep-
sin also showed weak direct activity at Par2 (Figure S6).
Purified recombinant matriptase can spontaneously cleave
itself from zymogen to active form (Takeuchi et al., 1999), but
how matriptase is activated in vivo and how such activation is
regulated is unknown. To probe the state of matriptase heterol-
ogously expressed in KOLFs and naturally expressed in HaCaT
cells and to further test the model that such matriptase can be
activated by prostasin and hepsin, we utilized specific anti-
bodies that distinguish two-chain, active matriptase from its
zymogen form (Benaud et al., 2001; Wang et al., 2009). Thec.
Figure 6. Evidence for a Cascade from Prostasin and Hepsin to Matriptase to Par2 Activation
(A) Inhibition of protease-triggered PI hydrolysis in HaCaT by E2 (2 mM), an active site-blocking antibody to matriptase.
(B) Par2 cleavage by prostasin in KOLFs transiently transfected with expression vectors for mouse AP-Par2, Hai-1, and full-length matriptase as indicated.
AP release in response to the addition of soluble recombinant prostasin or matriptase (50 nM) was measured. In (A) and (B), data shown are mean ± SD.
(C) Immunoblot analysis ofmatriptase processing by prostasin and hepsin in KOLFs transfectedwith Hai-1 alone or Hai-1 plusmatriptase ormatriptase active site
mutant (asm) expression vectors. Cultures were treated with the soluble recombinant protease domains (50 nM) indicated at the top; lysates were immunoblotted
with M69 and M24 matriptase antibodies, which recognize the active processed form and total matriptase, respectively.
(D) Conversion of endogenously expressed matriptase zymogen to its active form by prostasin and hepsin in HaCaT cultures. Cultures were treated with the
indicated soluble recombinant protease domains, and cell lysates analyzed as in (C). The tubulin blot served as a loading control. See also Figure S6.
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nonreducing SDS-PAGE was also exploited to detect the forma-
tion of active matriptase (Oberst et al., 2003).
Lysates of KOLFs transfected with Hai-1 plus vector or matrip-
tase were analyzed by immunoblot with M69 and M24 anti-
bodies; M69 recognizes the processed active form, and M24
recognizes both zymogen and active forms (Wang et al., 2009).
In the absence of added protease, matriptase andHai-1 cotrans-
fection resulted in the appearance of a 70 kDa band recognized
by M24 but not M69, consistent with expression of matriptase in
its zymogen form (Figure 6C, lane 4). Treatment with soluble
recombinant-active matriptase, prostasin, or hepsin caused the
appearance of a matriptase transfection-dependent 120 kDa
band recognized by M69, consistent with the appearance of
active matriptase complexed with Hai-1 (Figure 6C, lanes 5–7).
Prostasin was consistently the most active in this regard. The
intensity of the 70 kDa zymogen band recognized by M24 was
concomitantly decreased, consistent with conversion of matrip-
tase zymogen to its active form. The 65 kDa band in the M69
blots likely represents the Hai-1 complex of truncated soluble re-
combinant matriptase, which is not recognized by M24. Exoge-
nousmatriptase, prostasin, and hepsin treatment also converted
a matriptase active site mutant to a form recognized by M69 and
HAI-1, suggesting that matriptase activity and autoactivation areDevenot required to convert matriptase from its zymogen to its two-
chain form in this system (Figure 6C, lanes 9–11). These results
are consistent with amodel in which prostasin and hepsin cleave
and convert matriptase zymogen expressed on the surface of
KOLFs to its active form.
Similar results were obtained in HaCaT cells that naturally
express matriptase and HAI-1. In lysates of untreated HaCaTs,
matriptase was mainly in the zymogen form (Figure 6D, lanes
1–2, 70 kDa band in M24 panel). Addition of soluble recombi-
nant-active matriptase, prostasin, or hepsin caused the
appearance of the active form of matriptase migrating in com-
plex with Hai-1 (Figure 6D, lanes 3–8, 120 kDa band in M69
panel). This band was also recognized by Hai-1 immunoblot
(data not shown). Again, prostasin was the most active of the
three proteases tested in this assay. Taken together, our results
are consistent with the notion that prostasin and hepsin acti-
vate the zymogen form of matriptase on KOLF and HaCaT
cells.
Evidence for the Presence of Active Matriptase
at the Time and Place of Neural Tube Closure
The results outlined above suggest a model in which matriptase
and Par2 are coexpressed in the surface ectoderm, with matrip-
tase becoming activated locally in a manner that activates Par2lopmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Inc. 33
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coexpressed with its inhibitors, Hai-1 and -2 (Figure 4) (see
also Kirchhofer et al., 2003; List et al., 2005; Szabo et al.,
2008), and with its candidate activators prostasin and hepsin.
When and where active matriptase is made available to cleave
substrates in vivo is unknown (List et al., 2006). To determine
whether active matriptase is present at the same time and place
as Par2 during neural tube closure, we utilized E2 (Farady et al.,
2008) conjugated to Alexa Fluor 594 to stain live mouse embryos
collected at 8.5 dpc (Figure 4D; Figure S4). Antibody bound to
surface ectoderm in a distribution similar to that of Par2 expres-
sion. A control fluorescently labeled antibody showed no such
anatomically specific binding. These results suggest that the
matriptase active site is present on surface ectoderm cells at
the time and place of neural tube closure, consistent with the
model described above.
DISCUSSION
PARs function in the context of responses to injury in the adult
and contribute to cardiovascular development in the embryo.
Our results show an unexpected role for PARs and protease
signaling in regulating neural tube closure in the mouse embryo.
Our results also suggest that matriptase and other membrane-
tethered proteases coexpressed with Par2 may comprise a local
protease network that activates Par2 in this context. This para-
digm for autocrine/paracrine PAR activation raises interesting
questions regarding the roles of local protease signaling in
regulating epithelia, and the observation that Par2 and other
Gi-coupled GPCRs in surface ectoderm contribute to neural
tube closure inmicemay lead to insights into the complexmech-
anisms underlying human neural tube defects.
A Role for PARs and Gi Signaling in Neural Tube Closure
Duringneural tubeclosure in rodents, surfaceectoderm is thefirst
structure to close the gap between the opposing sides of the
open neural tube at the level of the hindbrain neuropore; at
most other levels, the neuroepithelium is the site of initial closure
(Geelen and Langman, 1979; Waterman, 1976). Exencephaly in
Par1/:Par2/, Grhl3Cre/+:ROSA26PTX/+, and Grhl3Cre/+:Rac1f/f
embryos suggests that disruption of GPCR, Gi, and Rac1
signaling in surface ectodermhampers neural tube closurewhere
surface ectoderm closure is an early event, but posterior neural
tube defects in Grhl3Cre/+:ROSA26PTX/+ and Grhl3Cre/+:Rac1f/f
embryos suggest that Gi pathway signaling in surface ectoderm
alsocontributeswhere the surfaceectodermclosesafter theneu-
roepithelium. Events during neural tube closure include fusion of
the neuroepithelium, fusion of the surface ectoderm, deadhesion
of the neuroepithelium from the surface ectodermand separation
of the closed ectoderm from the neural tube, differentiation
andmigration of neural crest cells between these structures, and
extensive remodeling of the extracellular matrix (Geelen and
Langman, 1979;GreeneandCopp, 2009; Schoenwolf andSmith,
1990; Waterman, 1976; Zohn and Sarkar, 2008). Par2, Gi, and
Rac regulate multiple cellular events, including reorganization of
the actin cytoskeleton, lamellipod formation, cell spreading,
polarization and migration, integrin and cadherin function, and
other cellular processes. Which of these accounts for the pheno-
types described herein remains to be determined.34 Developmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier InThe similarity of the Grhl3 and Par2 expression patterns
prompted us to use Grhl3 to drive Cre recombinase expression
for surface ectoderm-specific excision of floxed alleles. Intrigu-
ingly, the 50 region of Par2 contains several potential Grhl3-
binding sites. Gel shift assays confirmed that these sites bind
protein in a sequence-specific manner, but decreased Par2
expression in surface ectoderm was not detected in Grhl3 nulls
(data not shown). Whether Grhl3 participates in the control of
Par2 expression and whether and how these genes might
interact to contribute to neural tube closure remain to be deter-
mined. Regardless, Grhl3-Cre should be useful for the excision
of floxed alleles in surface ectoderm.
Candidate Par2-Activating Proteases during Neural
Tube Closure
The finding that Par2 contributes to neural tube closure raised
the question of what this receptor senses biochemically and
physiologically. An answer requires identifying the protease(s)
that activates Par2 in this context. Proteases reproducibly
shown to cleave PARs productively have been extracellular
serine proteases. Accordingly, we focused on secreted, GPI-
linked, and integral membrane proteins with an extracellular
serine protease domain that are expressed in embryos at the
time of neural tube closure as candidate Par2 activators. Anal-
ysis of Par2 and protease expression patterns, abundance in
embryos collected at 8.5–9.25 dpc, expression in surface ecto-
derm at this time, and functional testing all pointed to matriptase
as a strong candidate Par2 activator during neural tube closure.
Matriptase is a type-2 transmembrane protein with a serine
protease domain at its extracellular carboxyl terminal. We previ-
ously identified matriptase as a potential Par2 activator based
on its P1-P4 substrate sequence preference and found that
recombinantmatriptase protease domain activated Par2 heterol-
ogously expressed in Xenopus oocytes (Takeuchi et al., 2000).
However, the EC50 for Par2-dependent signaling in this system
was relatively high (>10 nM), and there was no obvious context
in which to determine whether matriptase was a physiological
Par2 activator. In the current study, recombinant matriptase
productively cleaved and activated Par2 expressed in mamma-
lian cells with an EC50 in the 200–300 pM range. Whether the
difference in EC50s in the Xenopus and mammalian systems is
due to differences in temperature (25C versus 37C), protease
inhibitors, or other factors is unknown. Regardless, the impres-
sive potency of soluble recombinant matriptase for Par2 activa-
tion in mammalian cells and the fact that the matriptase protease
domain is normally tethered to the cell surface suggests that ma-
triptase might be a physiological activator of Par2 in cells that
express both protease and receptor. Detection of matriptase
mRNA in surface ectoderm (Figures 4A and 4C) and binding of
amatriptaseactivesite-specificantibody to thesurfaceectoderm
cells near the closing neural tube (Figure 4D; Figure S4) suggest
that active matriptase may indeed coexist with Par2 in vivo at
a time and place consistent with a role in neural tube closure.
Matriptase did not show agonist activity for Par1, and the
protease(s) that might activate Par1 in its possible back-up role
in neural tube closure is unknown. No neural tube defects were
reported in the matriptase knockout mice (List et al., 2002), but
none would be expected if Par1 were activated by a matrip-
tase-independent mechanism.c.
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Trigger Par2 Signaling
Several observations suggest that prostasin, which is GPI linked
to the cell surface, might interact with matriptase and contribute
to Par2 activation. Prostasin is coexpressed with matriptase as
well as Hai-1 and Hai-2, Kunitz-type inhibitors for both prote-
ases, in many tissues (List et al., 2007) including surface ecto-
derm at the time of neural tube closure (Figure 4), and knockouts
of the prostasin and matriptase genes in mouse exhibit similar
phenotypes (defective skin development and barrier function)
(Leyvraz et al., 2005; List et al., 2002). Both proteases are also
tightly coexpressed with Par2 (Figure 4) (Bhatt et al., 2007).
Whereas soluble recombinant matriptase appeared to activate
Par2 directly, soluble recombinant prostasin activated Par2 indi-
rectly by a matriptase-dependent mechanism (Figures 5 and 6).
The simplest model consistent with these and other data is that
prostasin converts matriptase from a zymogen form to an active
form that can in turn activate Par2. In accord with this model, we
recently observed that, like loss of matriptase inhibition (Szabo
et al., 2009b), overexpression of either proprostasin or Par2 in
mouse skin led to ichthyosis, and that Par2 deficiency rescued
skin abnormalities caused by prostasin overexpression (S. Fra-
teschi, E.C., S.R.C., E. Hummler, and colleagues, unpublished
data). Par2 dependence of matriptase gain-of-function pheno-
types was not addressed (Szabo et al., 2009b).
Although hepsin was expressed more broadly than matrip-
tase, prostasin, and Par2, it was expressed in surface ectoderm
during neural tube closure, and, like prostasin, a soluble
recombinant hepsin that included its protease domain showed
matriptase-dependent signaling activity (Figures 5 and 6). Hep-
sin is a type-2 transmembrane protein with an extracellular
protease domain, and cell surface-localized hepsin might well
be an effective matriptase activator.
Epitheliasin, another type-2 transmembrane protein with an
extracellular protease domain that was expressed in surface
ectoderm during neural tube closure, was often coexpressed
with matriptase and Par2 (Figure 4). We did not detect epithelia-
sin-triggered signaling activity in either HaCaTs or matriptase
and PAR2-expressing KOLFs, but PAR2-dependent signaling
in LNCaP cells has been reported (Wilson et al., 2005). Epithelia-
sin might use an indirect mechanism to activate PAR2 in LNCaP
cells that requires components present in LNCaP cells but
absent in the HaCaT and KOLF systems.
Consistent with the mechanism proposed above for matrip-
tase-dependent Par2 activation by prostasin, our data suggest
that matriptase naturally expressed in HaCaTs or coexpressed
with Hai-1 in KOLFs exists predominantly in the zymogen form
and is converted to the active form upon addition of active pros-
tasin or hepsin (Figures 6C and 6D). Thus, Par2 activation in
surface ectoderm cells that also express matriptase might be
regulated at the level of matriptase activation. How matriptase
activation is regulated in vivo is unknown. Although our results
suggest that prostasin can activate matriptase, there is strong
evidence that matriptase is necessary for normal prostasin acti-
vation, at least in skin (Netzel-Arnett et al., 2006). Together, these
observations raise the possibility that prostasin might function
both downstream and upstream of matriptase to constitute
a positive-feedback loop. Ready examples of this paradigm exist
in the coagulation cascade, in which the effector proteaseDevethrombin activates upstream coagulation factors that mediate
thrombin generation to amplify thrombin production and propa-
gate coagulation in time and space (Broze, 1995).
Possible Physiological Roles for Membrane-Tethered
Protease/Par2 Signaling
Intriguingly, although matriptase and prostasin are often
expressed in the same epithelial cell, they may sort to distinct
membrane compartments, with matriptase directed basolater-
ally and prostasin apically (Godiksen et al., 2008; Wang et al.,
2009). Could it be that a prostasin-matriptase-Par2 network
has evolved to sense breaks in epithelial barrier function, in
which loss of cell-cell junctions allows for mixing of compart-
ments such that the proteases make contact, activate, and
trigger activation of Par2 and other effectors? And/or might
this system function at the edges of closing epithelial sheets
or in immature epithelium, where junctions and apical-basal
polarity have not yet been established such that protease inter-
action and activation is permitted? Our detection of active
matriptase predominantly at the edges of the surface ectoderm
during neural tube closure is consistent with models that include
such localized protease activation.
It was recently reported that deficiency of the protease inhib-
itor Hai-2 causes neural tube closure defects in mouse embryos
that were partially rescued by concomitant matriptase deficiency
(Szabo et al., 2009a). If matriptase activates Par2, howmightma-
triptase gain of function and Par2 loss of function yield similar
phenotypes? Gain of matriptase function might result in the
increased cleavage of other physiological substrates and/or
the cleavage of nonphysiological substrates to disrupt neural
tube closure by a mechanism unrelated to Par2 activation. Alter-
natively, loss of matriptase inhibitionmight disrupt normal spatial
and temporal control of Par2 activation, and/or excess matrip-
tase activity might downregulate Par2, effectively causing loss
of Par2 function. Either mechanism might disrupt the precise
tissue remodeling that occurs during neural tube closure (Massa
et al., 2009). Regardless, this report supports the notion that ma-
triptase is normally expressed and active in or around the closing
neural tube, consistent with the model outlined above.
Might the paradigm of membrane-tethered or locally secreted
proteases acting via Par2 to regulate epithelial function extend
beyond neural tube closure? Expression profiling confirms a tight
link in the expression of Par2, matriptase, prostasin, and epithe-
liasin across epithelial organs in adult mice, suggesting a poten-
tial functional link in adult biology as well. There are several
reported roles for these proteases in regulating external barriers
and in tumor progression where Par2 might be explored as
a candidate effector (Bhatt et al., 2007; Klezovitch et al., 2004;
Leyvraz et al., 2005; List et al., 2002, 2005, 2009). Like prostasin
overexpression and matriptase gain-of-function, overexpres-
sion of Par2 in skin leads to hyperkeratosis, stratum corneum
detachment, and itching (E.C. and S.R.C., unpublished data).
Similar phenotypes have been reported for overexpression of
Klk7 (Hansson et al., 2002), and excessive Klk5 activity
secondary to loss of Kazal-type-related inhibitor (LektI; encoded
by the Spink5 gene) has been suggested to drive stratum cor-
neum detachment in Netherton syndrome in a PAR2-dependent
manner (Briot et al., 2009). KLK5 has been reported as a PAR2
activator (Oikonomopoulou et al., 2006); we have confirmedlopmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Inc. 35
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dent activation of Par2 like prostasin (data not shown). PAR2 has
a complex role in inflammation in the gastrointestinal tract
(Vergnolle, 2000); tryptase, trypsin, and Xa have been proposed
activators in this context, but type-2 transmembrane serine
proteases are highly expressed in gut epithelium and might
well play a role. Together with our results, these observations
support exploration of the notion that local networks of mem-
brane-tethered proteases and Par2 might contribute to the regu-
lation of epithelial function in homeostasis and disease.
EXPERIMENTAL PROCEDURES
Nomenclature
Gene names are italicized. Human genes and proteins are in capital
letters (ST14, ST14); mouse has the first letter capitalized (St14, St14).
Protease-activated receptors (PARs) are designated by their commonly
used designation, Par1, Par2, etc. (their HUGO gene names are F2r, F2rl1,
etc.). PARs is used to refer to the family generically. Genes encoding Grhl3;
the G protein a subunits Ga12, Ga13, and Gaz; and matriptase are designated
Grhl3; Ga12, Ga13, and Gaz; and St14, respectively. HUGO gene names for
Ga12, Ga13, and Gaz are Gna12, Gna13, and Gnaz, respectively.
Mice, Timed Matings, and Gross Analysis of Mouse Embryos
Experiments were performed in accordance with protocols approved by the
University of California, San Francisco Institutional Animal Care and Use
Committee. Generation of mutant mice is described in Supplemental Experi-
mental Procedures. The morning a vaginal plug was detected was considered
0.5 days postcoitus (dpc). For embryo collection, yolk sack and placenta were
removed intact and scored as described below, then embryos were removed,
examined, and photographed. Before 12.5 dpc, viability was scored by the
presence or absence of a heartbeat. At or after 12.5 dpc, the presence of
pulsation in vitelline or umbilical vessels or response to pinch was used. In
some cases, embryos and deciduas were fixed en bloc and processed for
paraffin embedding and sectioning.
X-Gal Staining and In Situ Hybridization
Embryos were fixed, processed for X-gal staining (Supplemental Experimental
Procedures) (Griffin et al., 2001), then imaged or paraffin embedded, sectioned
at 5 mm, and counterstained with Nuclear Fast Red. For in situ hybridization,
9.0 dpc embryos were fixed in 4% paraformaldehyde, washed, and dehy-
drated. In situ hybridization was performed in whole mount or on 5 mm paraffin
sections (Henrique et al., 1995; Soifer et al., 1994); as outlined in Supplemental
Experimental Procedures.
Cell Culture and Cell Signaling Assays
HaCaTs and vector- and PAR-transfected KOLFs were grown in DMEM with
10% FBS, 100 units/ml penicillin, and 100 mg/ml streptomycin (Camerer
et al., 2000). KOLF, KOLFPAR2, or HaCaTs were transiently transfected with
pSPORT6 (Open Biosystems) and pCDNA3 (Invitrogen) expression vectors
carrying cDNAs for matriptase, matriptaseS805A, Hai-1, and/or human or
mouse PARs by electroporation (Amaxa Inc) or by using Mirus transfection
reagent (Mirus). The next day, the cells were washed and incubated in SFM
(serum-free DMEM with 20 mM HEPES and 0.1% bovine serum albumin
[BSA]) with 2 mCi/mL myo-[3H]inositol overnight, then washed again and incu-
batedwith SFM for 2 hr prior to the addition of agonist and LiCl for 90min. Cells
were then extracted, and released inositol phosphates were measured
(Camerer et al., 2000).
Receptor Cleavage Assay
AP-Par1 and AP-Par2 encoding secreted human placental alkaline phospha-
tase (SEAP) fused to the mouse PAR N terminus with an intervening linker
region were generated (Ludeman et al., 2004). Briefly, the coding regions of
Par1 and Par2 C-terminal to the signal peptidase site were PCR amplified
and ligated into the HpaI (50) and XbaI (30) sites of pCMV-SEAP (Tropix/Applied
Biosystems) such that the SEAP stop codon was removed and SEAP was36 Developmental Cell 18, 25–38, January 19, 2010 ª2010 Elsevier Injoined to each Par via an SGASGA linker. PCR-based site-directed mutagen-
esis was used to generate Par2R38A/S39P and Par1R41A/S42P cleavage site
mutants and to generate the matriptaseS805A in which the active site serine
was replaced by alanine (Takeuchi et al., 1999).
KOLF and HaCaT cells were transiently transfected with human or mouse
matriptase, matriptaseS805A, and/or Hai-1 together with AP-Par1 or AP-Par2
or their cleavage site mutants. The next day, cells were washed and incubated
in serum-freeM199with 25mMHEPES and 0.1%BSA for 2 hr and treatedwith
the indicated proteases for 60 min, and conditioned medium was assayed for
AP activity (Ludeman et al., 2004). The amount of intact receptor remaining on
the cell surface and still available for cleavage after treatment with test prote-
ases was determined by washing cells, then treating with trypsin (50 nM;
Sigma) for an additional 5 min, at which time conditioned medium was
collected and AP again measured. Data are presented as fold increase or
a percentage of total AP released (AP released by test protease/[same +
remaining surface AP released by trypsin]). For HaCaT cell studies, 1,10 phe-
nanthroline (5 mM) was added to the incubation medium to inhibit metallopro-
tease-dependent, nonproductive PAR shedding (Ludeman et al., 2004).
Matriptase Immunoblot
Cells were treated as indicated, washed twice with ice-cold Tris-buffered
saline (TBS), then lysed in 13 Laemmli sample buffer. Lysates were analyzed
by SDS/PAGE under nonboiling, nonreducing conditions, then blotted onto
nitrocellulose membranes. Membranes were incubated with mouse mono-
clonal antibodies for active (M69) or total (M24) matriptase (Wang et al.,
2009), then with horseradish peroxidase-conjugated goat anti-mouse IgG
(Invitrogen) and chemiluminescence detection reagents (GE Healthcare).
Statistical Analysis
Phenotype frequencies were analyzed by chi-square. Phosphoinositide hydro-
lysis and AP release assays were analyzed by one- or two-way ANOVA, fol-
lowed by t test for individual comparisons. Bonferroni correction for planned
multiple comparisons was included when appropriate. Single, double, and
triple asterisks (*) indicate p < 0.05, 0.01, and 0.001 compared to vehicle
control, respectively; not significant (ns) indicates p > 0.05. The findings
reported in Figures 5 and 6 were reproduced at least twice. Data shown are
mean ± standard deviation. N was 3 or greater, except for 6B (n = 2).
Additional Experimental Procedures
Please refer to Supplemental Information regarding the generation of mutant
mice, the protease database, qPCR array and analysis, E2 immunostaining
of embryos for active matriptase, and additional experimental procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, Supplemental Experimental
Procedures, and one spreadsheet and are available at doi:10.1016/j.devcel.
2009.11.014.
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